Meeting
2016 ASCO Annual Meeting
Pilot trial of intratumoral (IT) G100, a toll-like receptor-4 (TLR4) agonist, in patients (pts) with Merkel cell carcinoma (MCC): Final clinical results and immunologic effects on the tumor microenvironment (TME).
Authors
Shailender Bhatia
University of Washington - Fred Hutchinson Cancer Research Center, Seattle, WA
Shailender Bhatia , Natalie Miller , Hailing Lu , Dafina Ibrani , Michi Shinohara , David R. Byrd , Upendra Parvathaneni , Natalie Vandeven , Rima Kulikauskas , Jan Ter Meulen , Frank J. Hsu , David M Koelle , Paul Ngheim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Vaccines
Clinical Trial Registration Number
NCT02035657
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3021)
DOI
10.1200/JCO.2016.34.15_suppl.3021
Abstract #
3021
Poster Bd #
343
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma?
First Author: Chanjuan Shi
Poster
2024 ASCO Genitourinary Cancers Symposium
Alterations in tumor immune microenvironment and progressive immune exhaustion with advancing penile squamous cell carcinoma using multiplex immunofluorescence and image analysis.
First Author: Keerthi Gullapalli
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.
First Author: Jose Antonio Lopez Guerrero
Poster
2023 ASCO Annual Meeting
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
First Author: Miguel Angel Villalona-Calero